Increased epidermal growth factor receptor in fsn/fsn mice.
Cyclosporine: tu, Enzyme-Linked-Immunosorbent-Assay, Epidermal-Growth-Factor-Urogastrone: tu, Immunohistochemistry, Mice, Mice-Mutant-Strains: ge, me, Psoriasis: ge, me, th, Receptors-Epidermal-Growth-Factor-Urogastrone: me, Skin: in, me, pa, SUPPORT-U-S-GOVT-NON-P-H-S, SUPPORT-U-S-GOVT-P-H-S, Ultraviolet-Rays, Wounds-and-Injuries: me
J Invest Dermatol 1996 Jun;106(6):1169-74
GM40437/GM/NIGMS, P30AR41943/AR/NIAMS, AR40324/AR/NIAMS
Epidermal growth factor receptors (EGF-Rs) are elevated in active human psoriatic lesions, but decrease in resolving lesions. Similar biologic responses in EGF-R levels have been demonstrated within human psoriatic skin grafted onto mice. We tested the hypothesis that flaky-skin mice (fsn/fsn), one proposed genetic animal model of psoriasis, would display EGF-R levels comparable to human psoriatic epidermis and show similar biologic responses. EGF-R levels were characterized in unperturbed sites in fsn/fsn skin and +/? skin by enzyme-linked immunosorbent assay, 125I-EGF binding, and immunostaining. Altered EGF-R levels were noted after mild trauma (tape stripping) or under resolving conditions (30 doses of 50 mJ/CM2 ultraviolet B, 2.5 mg/kg oral cyclosporin A, or daily 30 microg/ml topical EGF). Increased EGF-R immunostaining was observed in involved flaky epidermal sites before treatment. To determine whether a hyperproliferative (Koebner) reaction could be induced, we tape stripped fsn/fsn tail and non-flaky dorsal sites. EGF-R levels in dorsal epidermis increased by days 3-4 after injury by enzyme-linked immunoabsorbent assay methods. When fsn/fsn mice received one of three different treatments for 6 weeks, the skin returned to a normal phenotype both grossly and microscopically. Immunoreactive EGF-R in treated, but not untreated, sites decreased to either normal or nondetectable levels. These data indicate that fsn/fsn mice exhibit an EGF-R profile identical to that of lesional and nonlesional human psoriatic epidermis. Modulations of the flaky phenotype in response to injury and three different treatments suggest that fsn/fsn is a useful in vivo model for examining new treatment modalities for psoriasiform skin diseases.
Nanney, L B.; Sundberg, J P.; and King, L E., " Increased epidermal growth factor receptor in fsn/fsn mice." (1996). Faculty Research 1990 - 1999. 749.